{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:34:44Z","timestamp":1780673684077,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T00:00:00Z","timestamp":1664409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100018764","name":"Semnan University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["1490"],"award-info":[{"award-number":["1490"]}],"id":[{"id":"10.13039\/501100018764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-022-01818-5","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T20:03:15Z","timestamp":1664481795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-tumor effect of berberine on chronic lymphocytic leukemia cells"],"prefix":"10.1007","volume":"39","author":[{"given":"Maryam","family":"Abdollahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mohammadlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Hemati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasoul","family":"Baharlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Manouchehri Doulabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2620-3378","authenticated-orcid":false,"given":"Farahnaz","family":"Ghahremanfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amir","family":"Sarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-4209","authenticated-orcid":false,"given":"Parviz","family":"Kokhaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"issue":"8","key":"1818_CR1","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","volume":"15","author":"JA Burger","year":"2018","unstructured":"Burger JA, O\u2019Brien S. Evolution of CLL treatment\u2014from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510\u201327.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"1818_CR2","doi-asserted-by":"publisher","first-page":"e00569","DOI":"10.1128\/MCB.00569-16","volume":"37","author":"X Sun","year":"2017","unstructured":"Sun X, et al. Ki-67 contributes to normal cell cycle progression and inactive X heterochromatin in p21 checkpoint-proficient human cells. Mol Cell Biol. 2017;37(17):e00569-e616.","journal-title":"Mol Cell Biol"},{"issue":"4","key":"1818_CR3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.32007\/jfacmedbagdad.544698","volume":"54","author":"SS AL-Mudallal","year":"2012","unstructured":"AL-Mudallal SS, Jasim HN. Evaluation of Bcl 2 and Ki 67 expression in Chronic Lymphocytic Leukemia. J Faculty Med Baghdad. 2012;54(4):335\u20139.","journal-title":"J Faculty Med Baghdad"},{"issue":"2","key":"1818_CR4","first-page":"318","volume":"23","author":"M-F Tan","year":"2015","unstructured":"Tan M-F, et al. Expression of ki-67 in chronic lymphocytic leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23(2):318\u201321.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"12","key":"1818_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34(12):592\u2013601.","journal-title":"Trends Immunol"},{"issue":"3","key":"1818_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.trecan.2016.02.005","volume":"2","author":"V Balatti","year":"2016","unstructured":"Balatti V, et al. Novel mechanisms of regulation of miRNAs in CLL. Trends in cancer. 2016;2(3):134\u201343.","journal-title":"Trends in cancer"},{"issue":"1","key":"1818_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00580-018-2671-z","volume":"28","author":"S Aref","year":"2019","unstructured":"Aref S, et al. Prognostic relevance of CD69 expression in B cell chronic lymphocytic leukemia. Comp Clin Pathol. 2019;28(1):33\u201340.","journal-title":"Comp Clin Pathol"},{"key":"1818_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/106713","author":"PT Diamantopoulos","year":"2014","unstructured":"Diamantopoulos PT, et al. PARP1-driven apoptosis in chronic lymphocytic leukemia. BioMed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/106713.","journal-title":"BioMed Res Int"},{"key":"1818_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.critrevonc.2017.05.008","volume":"116","author":"SH Ayati","year":"2017","unstructured":"Ayati SH, et al. Regulatory effects of berberine on microRNome in cancer and other conditions. Crit Rev Oncol Hematol. 2017;116:147\u201358.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1818_CR10","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CMAR.S242329","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. The anti-cancer mechanisms of berberine: a review. Cancer Manag Res. 2020;12:695.","journal-title":"Cancer Manag Res"},{"issue":"4","key":"1818_CR11","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ptr.6945","volume":"35","author":"M Mohammadlou","year":"2021","unstructured":"Mohammadlou M, et al. Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients with B-chronic lymphocytic leukemia. Phytother Res. 2021;35(4):2025\u201333.","journal-title":"Phytother Res"},{"issue":"25","key":"1818_CR12","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"3","key":"1818_CR13","first-page":"634","volume":"19","author":"F Ghahremanfard","year":"2017","unstructured":"Ghahremanfard F, et al. Effect of berberine on cancer cell viability of chronic lymphocytic leukemia patients in in vitro. Koomesh. 2017;19(3):634\u201340.","journal-title":"Koomesh"},{"issue":"11","key":"1818_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1373\/clinchem.2015.239459","volume":"61","author":"H Schwarzenbach","year":"2015","unstructured":"Schwarzenbach H, et al. Data normalization strategies for microRNA quantification. Clin Chem. 2015;61(11):1333\u201342.","journal-title":"Clin Chem"},{"issue":"13","key":"1818_CR15","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","volume":"125","author":"P Jain","year":"2015","unstructured":"Jain P, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062\u20137.","journal-title":"Blood"},{"issue":"26","key":"1818_CR16","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017\u201323.","journal-title":"Blood"},{"issue":"3","key":"1818_CR17","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1007\/s13277-015-4217-1","volume":"37","author":"L Ciszak","year":"2016","unstructured":"Ciszak L, et al. Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody. Tumor Biology. 2016;37(3):4143\u201357.","journal-title":"Tumor Biology"},{"issue":"2","key":"1818_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1006\/excr.2000.4888","volume":"257","author":"E Endl","year":"2000","unstructured":"Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231\u20137.","journal-title":"Exp Cell Res"},{"key":"1818_CR19","first-page":"7","volume":"3","author":"O Khoudoleeva","year":"2011","unstructured":"Khoudoleeva O, et al. Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients. Pathol Lab Med. 2011;3:7\u201316.","journal-title":"Pathol Lab Med"},{"issue":"2","key":"1818_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056666","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang L, et al. Berberine inhibits proliferation and down-regulates epidermal growth factor receptor through activation of Cbl in colon tumor cells. PLoS ONE. 2013;8(2): e56666.","journal-title":"PLoS ONE"},{"issue":"1\u20133","key":"1818_CR21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejphar.2012.05.004","volume":"688","author":"KNC Murthy","year":"2012","unstructured":"Murthy KNC, Jayaprakasha GK, Patil BS. The natural alkaloid berberine targets multiple pathways to induce cell death in cultured human colon cancer cells. Eur J Pharmacol. 2012;688(1\u20133):14\u201321.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20133","key":"1818_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.021","volume":"661","author":"K Yan","year":"2011","unstructured":"Yan K, et al. Induction of G1 cell cycle arrest and apoptosis by berberine in bladder cancer cells. Eur J Pharmacol. 2011;661(1\u20133):1\u20137.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1818_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11010-019-03529-4","volume":"458","author":"J Tak","year":"2019","unstructured":"Tak J, et al. Berberine enhances posttranslational protein stability of p21\/cip1 in breast cancer cells via down-regulation of Akt. Mol Cell Biochem. 2019;458(1):49\u201359.","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"1818_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/blood-2014-03-559690","volume":"124","author":"B Cui","year":"2014","unstructured":"Cui B, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124(4):546\u201354.","journal-title":"Blood"},{"issue":"13","key":"1818_CR25","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1158\/0008-5472.CAN-08-0511","volume":"68","author":"MK Pandey","year":"2008","unstructured":"Pandey MK, et al. Berberine modifies cysteine 179 of I\u03baB\u03b1 kinase, suppresses nuclear factor-\u03baB\u2013regulated antiapoptotic gene products, and potentiates apoptosis. Can Res. 2008;68(13):5370\u20139.","journal-title":"Can Res"},{"issue":"10","key":"1818_CR26","doi-asserted-by":"publisher","first-page":"e3070","DOI":"10.1038\/cddis.2017.471","volume":"8","author":"D Hou","year":"2017","unstructured":"Hou D, et al. Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition. Cell Death Dis. 2017;8(10):e3070\u2013e3070.","journal-title":"Cell Death Dis"},{"issue":"1\u20133","key":"1818_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejphar.2010.07.037","volume":"645","author":"JB Patil","year":"2010","unstructured":"Patil JB, Kim J, Jayaprakasha G. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol. 2010;645(1\u20133):70\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1818_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2011.052829","volume":"97","author":"G Del Poeta","year":"2012","unstructured":"Del Poeta G, et al. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. Haematologica. 2012;97(2):279.","journal-title":"Haematologica"},{"issue":"4","key":"1818_CR29","first-page":"295","volume":"2","author":"L Xu","year":"2005","unstructured":"Xu L, Liu Y, He X. Inhibitory effects of berberine on the activation and cell cycle progression of human peripheral lymphocytes. Cell Mol Immunol. 2005;2(4):295\u2013300.","journal-title":"Cell Mol Immunol"},{"issue":"21","key":"1818_CR30","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SE Herman","year":"2014","unstructured":"Herman SE, et al. Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123(21):3286\u201395.","journal-title":"Blood"},{"issue":"3","key":"1818_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","volume":"5","author":"Y-X Chen","year":"2020","unstructured":"Chen Y-X, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267\u201375.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"1818_CR32","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1111\/jcmm.12119","volume":"17","author":"J Zhang","year":"2013","unstructured":"Zhang J, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signalling. J Cell Mol Med. 2013;17(11):1484\u201393.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1818_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-5791-1","volume":"19","author":"J Xu","year":"2019","unstructured":"Xu J, et al. Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):1\u201320.","journal-title":"BMC Cancer"},{"issue":"6","key":"1818_CR34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1124\/mol.114.094037","volume":"86","author":"S-C Chu","year":"2014","unstructured":"Chu S-C, et al. Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol Pharmacol. 2014;86(6):609\u201323.","journal-title":"Mol Pharmacol"},{"key":"1818_CR35","doi-asserted-by":"publisher","first-page":"11751","DOI":"10.2147\/OTT.S235667","volume":"12","author":"P Zhang","year":"2019","unstructured":"Zhang P, et al. Berberine inhibits growth of liver cancer cells by suppressing glutamine uptake. Onco Targets Ther. 2019;12:11751\u201363.","journal-title":"Onco Targets Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-022-01818-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-022-01818-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T04:09:52Z","timestamp":1701144592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-022-01818-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1818"],"URL":"https:\/\/doi.org\/10.1007\/s12032-022-01818-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study complied with the guidelines for human studies and was conducted in accordance with the World Medical Association Declaration of Helsinki. The study protocol was approved by the Ethical Board of the Semnan University of Medical Sciences (IR.SEMUMS.REC.1379.181).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individuals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable, as data of the study was anonymous.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"217"}}